Talk:Dextrorphan

This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.

This page has not been fully approved by the PsychonautWiki administrators. It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: Dextrorphan

Dextrorphan
Chemical Nomenclature
Common names	DXO
Substitutive name	Dextrorphan
Systematic name	(+)-17-methyl-9a,13a,14a-morphinan-3-ol
Class Membership
Psychoactive class	Dissociative
Chemical class	Morphinan
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Oral Dosage Threshold 80 mg Light 100 - 150 mg Common 150 - 300 mg Strong 300 - 450 mg Heavy 450 mg+ Duration DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions
Benzodiazepines
Cannabis
DOx
25x-NBOMe
2C-T-x
5-MeO-xxT
Amphetamines
Cocaine
ΑMT
PCP
MDMA
Alcohol
GHB
GBL
Opioids
Tramadol
MAOIs
SSRIs
Antihistamines

Dextrorphan (also known as DXO) is a dissociative drug of the morphinan class. It's the main active metabolite of dextromethorphan (DXM). It appears as a colorless powder.

Chemistry

Dextrorphan is a dextrorotatory molecule of the morphinan class. It contains a phenanthrene core structure with one aromatic ring (benzene) bound to two saturated rings (cyclohexane). Dextromethorphan is metabolized in the body by o-demethylation through the CYP2D6 enzyme to form Dextrorphan.

Pharmacology

The pharmacology of dextrorphan is similar to that of dextromethorphan (DXM). However, dextrorphan is much more potent as an NMDA receptor antagonist as well as essentially inactive as a serotonin reuptake inhibitor. DXO is an active chemical and contributes to the subjective effects experienced when active doses of DXM are consumed.

Binding affinities (K_i)

• NMDA antagonist - 486 nM
• Sigma-1 agonist - 351 nM
• Serotonin transporter (SERT) - 484 nM
• Mu opioid agonist - 420 nM

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

One user reported excessive itchiness accompanied by a "peaceful yet emotionless state" after 340mg of the substance was consumed.

Physical effects

• • Appetite suppression
  • Changes in felt bodily form
  • Gustatory hallucinations
  • Itchiness - This effect has become subsequently known as "robo-itch" and though relatively common there are many users who never experience this particular effect while some individuals can experience it quite intensely.
  • Muscle spasms
  • Motor control loss
  • Pain relief
  • Perception of decreased weight
  • Physical autonomy
  • Spatial disorientation
  • Tactile disconnection
  • Tactile suppression

Cognitive effects

• • Amnesia
  • Conceptual thinking
  • Consciousness disconnection
  • Creativity enhancement
  • Déjà vu
  • Depersonalization
  • Derealization
  • Disinhibition
  • Existential self-realization
  • Immersion enhancement
  • Increased music appreciation
  • Information processing suppression
  • Memory suppression
  • Novelty enhancement
  • Personal bias suppression
  • Thought deceleration
  • Time distortion
  • Unity and interconnectedness

Experience reports

There are currently 0 experience reports which describe the effects of this substance in our experience index.

Additional experience reports can be found here:

• Erowid Experience Vaults: DXO

Toxicity and harm potential

This toxicity and harm potential section is a stub. As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.

It is strongly recommended that one use harm reduction practices when using this substance.

Dangerous interactions

This dangerous interactions section is a stub. As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• Depressants (e.g. 2M2B, alcohol, barbiturates, benzodiazepines, GHB/GBL, methaqualone, opioids) - This combination potentiates the muscle relaxation, amnesia, sedation, and respiratory depression caused by one another and at higher doses, can lead to a sudden, unexpected loss of consciousness along with dangerously depressed respiration. There is also an increased risk of vomiting while unconsciousness and dying from the resulting suffocation. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
• Stimulants (e.g. amphetamine, cocaine, methylphenidate, MDMA) - This combination can potentiate the anxiety-inducing, manic, delusional and disinhibiting effects of dissociatives, particularly those without pronounced motor suppressing components such as ketamine. The sum of these effects can increase the likelihood of an anxiety attack, delusions or a psychotic episode. There is also evidence that suggests that combining these two increases their neurotoxicity. Anecdotally, worsened comedowns are also commonly reported when these two classes of substances are combined.
• Dissociatives (e.g. dextromethorphan, ketamine, methoxetamine, PCP) - Combination can unpredictably potentiate amnesia, sedation, motor control loss and delusions. It may also result in a sudden loss of consciousness along with a dangerous amount of respiratory depression. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.

Legal issues

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

• Germany: Dextrorphan is uncontrolled.
• Poland: Dextrorphan is unscheduled.
• United States: Dextrorphan is unscheduled since October 1, 1976.

See also

• Responsible use
• Dextromethorphan
• Dissociative
• NMDA receptor antagonist
• Morphinan
• MXE

External links

• Dextrorphan (Wikipedia)